What laboratory tests should be ordered to evaluate a patient with long QT syndrome?

Laboratory Testing for Long QT Syndrome Evaluation

The primary laboratory tests for evaluating long QT syndrome are serum electrolytes (potassium, magnesium, and calcium), because electrolyte abnormalities—particularly hypokalemia and hypomagnesemia—are the most common reversible contributors to acquired long QT and must be corrected before attributing QT prolongation to other causes. 1

Essential Laboratory Panel

Immediate Electrolyte Assessment

• Serum potassium must be measured and corrected to > 4.0 mmol/L (optimally 4.5–5.0 mmol/L), as hypokalemia is a leading cause of acquired QT prolongation 1, 2
• Serum magnesium should be corrected to > 2.0 mg/dL; hypomagnesemia frequently coexists with hypokalemia, especially in patients on diuretics 1, 2
• Serum calcium must be normalized, as hypocalcemia can prolong the QT interval 1, 2

Additional Metabolic Screening

• Renal function (creatinine, eGFR) should be checked because renal impairment increases drug accumulation of QT-prolonging medications and heightens arrhythmia risk 1, 2
• Thyroid function tests (TSH, free T4) are warranted when hypothyroidism is suspected, as it can prolong the QT interval 1

Distinguishing Acquired from Congenital LQTS

When Electrolytes Normalize QTc

• If QTc normalizes to < 450 ms in men or < 460 ms in women after electrolyte correction and discontinuation of QT-prolonging drugs, the diagnosis is acquired long QT syndrome; genetic testing is not required 1, 2
• Permanent avoidance of QT-prolonging medications and regular electrolyte monitoring (especially in diuretic users) are mandatory 1, 2

When QTc Remains Elevated

• If QTc remains > 480 ms after correction of all reversible causes, congenital long QT syndrome should be suspected and the patient referred to an inherited arrhythmia clinic 1, 2
• Genetic testing for KCNQ1 (LQT1), KCNH2 (LQT2), and SCN5A (LQT3) can be considered, but only after thorough clinical phenotyping 1, 3
• Approximately 15–20% of patients with clinical congenital LQTS do not have a recognized genetic variant and are "genetically elusive" 1

High-Risk Populations Requiring Intensive Monitoring

• Female sex, advanced age, and structural heart disease are the highest-risk demographics for drug-induced QT prolongation 1, 2
• Patients on diuretics require serial electrolyte monitoring because they are prone to hypokalemia and hypomagnesemia 1, 2
• Renal or hepatic impairment necessitates regular monitoring of both electrolytes and renal function due to drug accumulation risk 1, 2

Common Clinical Pitfalls

• Do not overlook medication-induced QT prolongation; many "innocuous" agents such as macrolide antibiotics, fluoroquinolones, and common antidepressants (citalopram, escitalopram) can be culprits 1, 2
• Do not assume QT prolongation is congenital without first excluding all acquired causes, especially in patients over 50 years old 1, 2
• Always repeat the ECG after medication washout (five half-lives) and electrolyte correction; normalization confirms an acquired etiology and obviates unnecessary genetic testing 1, 2
• Do not ignore electrolyte monitoring in diuretic users; hypokalemia and hypomagnesemia are the most frequent contributors to acquired LQTS 1, 2